BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Sep 13, 2010
 |  BC Week In Review  |  Company News  |  Other News

Ark cancer, cardiovascular, gene/cell therapy news

Ark will restructure and reduce headcount by an undisclosed amount to focus on and seek partners for its vascular endothelial growth factor D (VEGF-D) programs for refractory angina and peripheral vascular disease, as well as its preclinical neuropilin 1 (NRP1) antagonist and fetal growth restriction programs. The company expects...

Read the full 241 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >